GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
A Study to Evaluate the One Year Long-term Persistence of Immune Responses Following Two Different Rabies Vaccine Post-exposure Regimens in Chinese Children
Phase 4
Withdrawn
- Conditions
- Virus Diseases
- Interventions
- Biological: Rabipur
- First Posted Date
- 2017-06-20
- Last Posted Date
- 2018-02-26
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT03192371
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the GlaxoSmithKline (GSK) Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine (GSK3003891A) in Healthy Pregnant Women and Infants Born to Vaccinated Mothers
Phase 2
Withdrawn
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Biological: RSV vaccine (GSK3003891A) formulation 2Biological: RSV vaccine (GSK3003891A) formulation 3Drug: Placebo (Formulation buffer S9b)Biological: RSV vaccine (GSK3003891A) formulation 1
- First Posted Date
- 2017-06-19
- Last Posted Date
- 2018-10-15
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT03191383
- Locations
- 🇪🇸
GSK Investigational Site, Sevilla, Spain
Safety, Tolerability and Pharmacokinetics (PK) Study of GSK2269557 in Healthy Subjects
Phase 1
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: GSK2269557 500 µgDrug: GSK2269557 750 µg
- First Posted Date
- 2017-06-16
- Last Posted Date
- 2019-08-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 12
- Registration Number
- NCT03189589
- Locations
- 🇬🇧
GSK Investigational Site, Cambridge, United Kingdom
Immunogenicity of a Single Dose of GSK Biologicals' Boostrix™ in Infants Prior to Primary Pertussis Vaccination, When Administered to Pregnant Women as Per Routine Practice in Bogota, Colombia
Phase 4
Terminated
- Conditions
- Diphtheria-Tetanus-Acellular Pertussis
- Interventions
- Other: Blood sample
- First Posted Date
- 2017-06-15
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 18
- Registration Number
- NCT03188458
- Locations
- 🇨🇴
GSK Investigational Site, Bogotá, Colombia
A Long-term Safety Study of Fixed Dose Combination Therapy Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate in Japanese Subjects With Asthma
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2017-06-14
- Last Posted Date
- 2020-05-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 111
- Registration Number
- NCT03184987
- Locations
- 🇯🇵
GSK Investigational Site, Toyama, Japan
Immunogenicity and Persistence of GlaxoSmithKline (GSK) Biologicals' Havrix® in Healthy Adult Subjects Vaccinated at Infancy Under the Hepatitis A Universal Mass Vaccination (UMV) Program in Israel
Phase 4
Withdrawn
- Conditions
- Hepatitis A
- Interventions
- Biological: Havrix®
- First Posted Date
- 2017-06-12
- Last Posted Date
- 2018-03-02
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT03183492
To Assess the Photosensitisation and Photoallergy Potential of a Cosmetic Facial Product in Healthy Participants
Not Applicable
Completed
- Conditions
- Skin Care
- Interventions
- Other: Facial micellar cleanser
- First Posted Date
- 2017-06-12
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 48
- Registration Number
- NCT03183518
- Locations
- 🇧🇷
GSK Investigational Site, Valinhos, Brazil
Arnuity® Ellipta® Drug Use Investigation
- First Posted Date
- 2017-06-12
- Last Posted Date
- 2021-04-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 336
- Registration Number
- NCT03184480
- Locations
- 🇯🇵
GSK Investigational Site, Nagasaki, Japan
Proof of Concept Anti-ageing Clinical Study in Healthy Subjects
Not Applicable
Completed
- Conditions
- Skin Aging
- Interventions
- Other: Test product (Moisturising cream)Other: No treatmentOther: Positive control (Commercial market place moisturising cream)
- First Posted Date
- 2017-06-08
- Last Posted Date
- 2019-07-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 72
- Registration Number
- NCT03180645
- Locations
- 🇩🇪
GSK Investigational Site, Schenefeld, Schleswig-Holstein, Germany
A Dose-escalation Study in Subjects With Pulmonary Arterial Hypertension (PAH)
- First Posted Date
- 2017-06-06
- Last Posted Date
- 2020-04-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 23
- Registration Number
- NCT03177603
- Locations
- 🇪🇸
GSK Investigational Site, Madrid, Spain
© Copyright 2025. All Rights Reserved by MedPath